Syndax Pharmaceuticals (NASDAQ: SNDX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Earnings and Valuation

This table compares Syndax Pharmaceuticals and BioMarin Pharmaceutical’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Syndax Pharmaceuticals $1.22 million 226.11 -$44.47 million ($2.83) -4.00
BioMarin Pharmaceutical $1.12 billion 14.40 -$630.21 million ($0.83) -110.36

Syndax Pharmaceuticals has higher earnings, but lower revenue than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Syndax Pharmaceuticals and BioMarin Pharmaceutical, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syndax Pharmaceuticals 0 0 8 0 3.00
BioMarin Pharmaceutical 0 5 15 1 2.81

Syndax Pharmaceuticals currently has a consensus target price of $26.43, suggesting a potential upside of 133.67%. BioMarin Pharmaceutical has a consensus target price of $114.00, suggesting a potential upside of 24.45%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Syndax Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Insider and Institutional Ownership

61.7% of Syndax Pharmaceuticals shares are held by institutional investors. Comparatively, 99.0% of BioMarin Pharmaceutical shares are held by institutional investors. 24.1% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


This table compares Syndax Pharmaceuticals and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Syndax Pharmaceuticals -4,304.34% -57.90% -45.09%
BioMarin Pharmaceutical -12.45% -4.60% -3.09%


BioMarin Pharmaceutical beats Syndax Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with's FREE daily email newsletter.